Lysophosphatidic acid receptor 2/3-mediated IL-8-dependent angiogenesis in cervical cancer cells

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages 789-802

  Chen, Ruey Jien ^a,b   Chen, Shee Uan ^a   Chou, Chia Hung ^a   Lin, Ming Chieh ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

angiogenesis; IL 8; LPA receptors; NF B; uterine cervical neoplasms

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN HYDROLYSATE; PROTEIN KINASE B; PROTEIN KINASE C; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; UTERINE CERVIX CANCER; XERORADIOGRAPHY;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DNA PRIMERS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-8; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE C; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 84862525932     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26476     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Chen RJ, Lin YH, Chen CA, Huang SC, Chow SN, Hsieh CY,. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999; 73: 184-90.
3. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP,. Markers of angiogenesis in high-risk, early-stage cervical cancer: a gynecologic oncology group study. Gynecol Oncol 2009; 112: 583-9.
4. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201. (Pubitemid 33063774)
5. Carmeliet P,. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95. (Pubitemid 30208155)
6. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T,. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res 2000; 60: 2632-5. (Pubitemid 30318237)
7. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS,. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000; 19: 4611-20.
8. Toussaint-Smith E, Donner DB, Roman A,. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 2004; 23: 2988-95. (Pubitemid 38648189)
9. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS,. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 2008; 110: 445-51.
10. Pages C, Simon MF, Valet P, Saulnier-Blache JS,. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 2001; 64: 1-10. (Pubitemid 32452277)
11. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 2000; 905: 188-208. (Pubitemid 30255418)
12. Schwartz BM, Hong G, Morrison BH, Wu W, Baudhuin LM, Xiao YJ, Mok SC, Xu Y,. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 2001; 81: 291-300. (Pubitemid 32424177)
13. Gschwind A, Prenzel N, Ullrich A,. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002; 62: 6329-36. (Pubitemid 35244489)
14. Mills GB, Moolenaar WH,. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-91. (Pubitemid 37328830)
15. Schafer B, Gschwind A, Ullrich A,. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004; 23: 991-9. (Pubitemid 38250945)
16. Murph M, Tanaka T, Liu S, Mills GB,. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res 2006; 12: 6598-602. (Pubitemid 44876826)
17. Tigyi G,. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010; 161: 241-70.
18. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J,. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010; 50: 157-86.
19. Xu X, Prestwich GD,. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antogonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010; 116: 1739-50.
20. Hu YL, Albanese C, Pestell RG, Jaffe RB,. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 2003; 95: 733-40. (Pubitemid 36665501)
21. Chen SU, Lee H, Chang DY, Chou CH, Chang CY, Chao KH, Lin CW, Yang YS,. Lysophosphatidic acid mediates interleukin-8 expression in human endometrial stromal cells through its receptor and nuclear factor-ηB-dependent pathway: a possible role in angiogenesis of endometrium and placenta. Endocrinology 2008; 149: 5888-96.
22. Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP, Chen CA, Hsieh CY,. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-ηB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 2005; 26: 45-52.
23. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G,. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-23. (Pubitemid 28405297)
24. Porter KR, Fonte V, Weiss G,. A scanning microscope study of the topography of HeLa cells. Cancer Res 1974; 34: 1385-94.
25. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A,. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115: 3057-71. (Pubitemid 41567571)
26. Zhao Y, Natarajan V,. Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal 2009; 21: 367-77.
27. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB,. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630-42.
28. Rivera-Lopez CM, Tucker AL, Lynch KR,. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 2008; 11: 301-10.
29. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, Serban M,. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 2008; 1781: 588-94.
30. Fishman DA, Liu Y, Ellerbroek SM, Stack MS,. Lysophosphatidic acid promotes matrix metalloprotein (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001; 61: 3194-9. (Pubitemid 32691975)
31. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Jr, Mills GB, Fang X,. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 2006; 66: 2740-8.
32. Kim MH, Park JS, Chang HJ, Baek MK, Kim HR, Shin BA, Ahn BW, Jung YD,. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells. J Cell Biochem 2008; 104: 1102-12.
33. Diefenbach CS, Soslow RA, Iasonos A, Linkov I, Hedvat C, Bonham L, Singer J, Barakat RR, Aghajanian C, Dupont J,. Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. Cancer 2006; 107: 1511-9. (Pubitemid 44546911)
34. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H,. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006; 281: 17492-500.
35. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB,. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004; 279: 9653-61. (Pubitemid 38296034)
36. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA,. LPA receptor 2 mediated LPA-induced endometrial cancer invasion. Gynecol Oncol 2009; 112: 215-23.
37. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, Rose TM, Prestwich GD, Xu Y,. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006; 66: 3006-14.
38. Ye X, Chun J,. Lysophosphatidic acid (LPA) signaling in vertebrate reproduction. Trends Endocrinol Metab 2010; 21: 17-24.
39. Hama K, Aoki J,. LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid. Prog Lipid Res 2010; 49: 335-42.
40. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH,. International union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 2010; 62: 579-87.
41. Noguchi K, Ishii S, Shimizu T,. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003; 278: 25600-6. (Pubitemid 36835313)
42. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, Owman C, Sillard R, Leeb-Lundberg LM, Olde B,. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 2006; 318: 619-28. (Pubitemid 44061237)
43. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J,. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006; 281: 23589-99.
44. Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nurnberg P, Nothen MM, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 2008; 40: 329-34. (Pubitemid 351311768)
45. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N,. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007; 363: 861-6. (Pubitemid 47516713)
46. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, An S,. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci USA 2005; 102: 6027-32. (Pubitemid 40594249)
47. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, et al. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 2010; 9: 140.
48. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, Kennedy G, Arai H, Aoki J, Chun J,. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005; 435: 104-8. (Pubitemid 40655916)
49. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008; 100: 359-72. (Pubitemid 351480526)